Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

Onconova Therapeutics

NEWTOWN, PA — Onconova Therapeutics, Inc. (NASDAQ: ONTX)  announced that a late-breaking abstract reporting the use of rigosertib in patients with recessive dystrophic epidermolysis bullosa (RDEB) associated with advanced/metastatic squamous cell carcinoma (SCC) will be presented in the Late Breaking News session at the European Academy of Dermatology and Venereology (EADV) 2023 Congress taking place October 11-14 in Berlin, Germany.

Presentation Details

  • Date: Thursday, October 12, 2023
  • Time: 4:00-4:15 p.m. in Germany / 10:00-10:15 a.m. ET
  • Abstract Title: Efficacy and Safety of Rigosertib in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) Associated Advanced/Metastatic Squamous Cell Carcinoma (SCC)
  • Presenter: Prof. Dr. Johann Bauer, MD, University Hospital Salzburg
  • Session: D2T01.3: Late breaking news

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.

READ:  Psych Congress Elevate 2024 Announces Leadership for Upcoming Conference